Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to carrying a high risk of bowel cancer, also greatly increases the risk of duodenal cancer. At present, the only ...

(RTTNews) - Tempest Therapeutics (TPST), a clinical-stage biotechnology company focused on cancer therapies, announced Thursday that it has received a "Study May Proceed" letter from the U.S. Food and ...

Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...

ROCHESTER, Minn. — Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying a rare genetic condition called Familial Adenomatous ...

Adding an esophagogastroduodenoscopy to a screening or surveillance colonoscopy detected upper-GI cancers and preneoplastic ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to a high risk of bowel cancer, also a greatly increased risk of duodenal cancer. At present, the only treatment ...